Exton, USA, November 8, 2006. Isolagen, Inc. (Amex: ILE) announced today its intention, subject to consultation with its UK workforce, to close Isolagen Europe Ltd., its UK operations.
"The closure of the UK operations is a difficult decision based on a full business analysis," said Nicholas L. Teti, Isolagen Chairman and Chief Executive Officer. "While we value the hard work and commitment of our UK staff, sustaining further financial losses in the UK business is not in the Company's best interest."
---xxx---
Isolagen Process
Isolagen’s patented autologous (a patient’s own cells) living cell therapy, or ACS, begins with the injection of a local anesthetic to numb a small section of skin behind the ear. This area was chosen because of its vascularity, lack of sun exposure, and the invisibility of any scarring.
2007-03-03 06:38:34
·
answer #1
·
answered by Apolo 6
·
0⤊
0⤋